{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:41:37Z","timestamp":1791902497618,"version":"4.3.4"},"reference-count":178,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":629,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016875","name":"Chimerix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jtct.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T19:10:34Z","timestamp":1629832234000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["American Society for Transplantation and Cellular Therapy Series: #3\u2014Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"27","author":[{"given":"Morgan","family":"Hakki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Danziger-Isakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian G.","family":"Michaels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco M.","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_1","key":"10.1016\/j.jtct.2021.05.001_bib0001","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/infdis\/jiy083","article-title":"The damage-response framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases","volume":"218","author":"Pirofski","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0002","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtct.2020.10.004","article-title":"American Society for Transplantation and Cellular Therapy Infectious Diseases Guidelines: preface to the series","volume":"27","author":"Carpenter","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2021.05.001_bib0003","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0004","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1462-5822.2012.01774.x","article-title":"Human cytomegalovirus persistence","volume":"14","author":"Goodrum","year":"2012","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0005","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.05.001_bib0006","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0007","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.001_bib0008","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0009","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0010","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0011","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-04-713644","article-title":"Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia","volume":"128","author":"Elmaagacli","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0012","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0013","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2016.89","article-title":"Impact of early CMV reactivation in cord blood stem cell recipients in the current era","volume":"51","author":"Ramanathan","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0014","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0015","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2020.04.002","article-title":"Favorable effect of cytomegalovirus reactivation on outcomes in cord blood transplant and its differences among disease risk or type","volume":"26","author":"Yokoyama","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2021.05.001_bib0016","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Post-transplant cyclophosphamide (PTCy) is associated with increased cytomegalovirus infection: A CIBMTR Analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.001_bib0017","doi-asserted-by":"crossref","first-page":"e13548","DOI":"10.1111\/tid.13548","article-title":"Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance","volume":"23","author":"Lindsay","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0018","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.001_bib0019","doi-asserted-by":"crossref","first-page":"e2017","DOI":"10.1002\/rmv.2017","article-title":"Going beyond serology for stratifying the risk of CMV infection in transplant recipients","volume":"29","author":"Navarro","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S0950268808000551","article-title":"Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III","volume":"137","author":"Dowd","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jtct.2021.05.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2018.04.043","article-title":"Racial and ethnic differences in the prevalence of congenital cytomegalovirus infection","volume":"200","author":"Fowler","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.jtct.2021.05.001_bib0022","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bbmt.2009.02.009","article-title":"Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation","volume":"15","author":"Nakamae","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0023","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.bbmt.2012.02.008","article-title":"Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients","volume":"18","author":"Pergam","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0024","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/tmrv.2001.19946","article-title":"Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction","volume":"15","author":"Blajchman","year":"2001","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtct.2021.05.001_bib0027","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598","article-title":"Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant","volume":"86","author":"Bowden","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0028","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/00365540110080412","article-title":"Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors","volume":"34","author":"Ljungman","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0029","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/blood-2002-10-3143","article-title":"Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products","volume":"101","author":"Nichols","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0030","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1046\/j.1537-2995.2001.41101310.x","article-title":"Evidence-based recommendations for the use of WBC-reduced cellular blood components","volume":"41","author":"Ratko","year":"2001","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2021.05.001_bib0031","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08227.x","article-title":"Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction","volume":"150","author":"Kerkhoffs","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0032","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2002-03-0932","article-title":"Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial","volume":"101","author":"van Rhenen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0033","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","article-title":"Impact of donor CMV-status on viral infection and reconstitution of multi-function CMV-specific T-cells in CMV-positive transplant recipients","volume":"113","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0034","first-page":"78","article-title":"Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation","volume":"91","author":"Ljungman","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.05.001_bib0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1705699","article-title":"Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies","volume":"40","author":"Ozdemir","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0036","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbmt.2011.05.015","article-title":"CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus","volume":"18","author":"Mikulska","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0037","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0038","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0039","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/infdis\/164.3.483","article-title":"Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant","volume":"164","author":"Bowden","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bmt.1700649","article-title":"No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group","volume":"19","author":"Ruutu","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0041","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJM198604173141602","article-title":"Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation","volume":"314","author":"Bowden","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.05.001_bib0042","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00007890-199707150-00020","article-title":"Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture","volume":"64","author":"Boeckh","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2021.05.001_bib0043","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1128\/JCM.00797-08","article-title":"Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients","volume":"46","author":"Gimeno","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0044","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1399-3062.2006.00171.x","article-title":"Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation","volume":"9","author":"Ksouri","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0045","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1373\/49.10.1683","article-title":"Quantitative real-time PCR compared with pp65 antigen detection for cytomegalovirus (CMV) in 1122 blood specimens from 77 patients after allogeneic stem cell transplantation: which test better predicts CMV disease development?","volume":"49","author":"Nitsche","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtct.2021.05.001_bib0046","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.bmt.1703513","article-title":"Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction","volume":"29","author":"Yakushiji","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0047","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0048","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1111\/bcp.13376","article-title":"Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0049","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/bcp.13292","article-title":"Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jtct.2021.05.001_bib0051","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/jcph.1423","article-title":"Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil","volume":"59","author":"McCrea","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0052","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkz499","article-title":"Clinically significant drug interaction: letermovir and voriconazole","volume":"75","author":"Duong","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jtct.2021.05.001_bib0053","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jcph.1094","article-title":"Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects","volume":"58","author":"Marshall","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jtct.2021.05.001_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00274-21","article-title":"Concomitant administration of posaconazole and isavuconazole with letermovir: clinical and pharmacological considerations","volume":"65","author":"Terrier","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2021.05.001_bib0055","unstructured":"Corp MSD. PREVYMIS: Package Insert and Label Information. 2017."},{"issue":"7","key":"10.1016\/j.jtct.2021.05.001_bib0056","doi-asserted-by":"crossref","first-page":"e13866","DOI":"10.1111\/ctr.13866","article-title":"Clinical \"real-world\" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients","volume":"34","author":"Anderson","year":"2020","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2021.05.001_bib0057","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-020-04362-2","article-title":"Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data","volume":"100","author":"Derigs","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0058","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.bbmt.2020.07.002","article-title":"Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant","volume":"26","author":"Johnsrud","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.001_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.10.009","article-title":"Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"27","author":"Lin","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2021.05.001_bib0060","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13187","article-title":"Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0061","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","article-title":"Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data","volume":"56","author":"Mori","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0062","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0730-y","article-title":"Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation","volume":"55","author":"Sharma","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0063","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/ajt.16450","article-title":"Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection","volume":"21","author":"Cassaniti","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0064","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French Compassionate Program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.001_bib0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0066","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtct.2021.05.001_bib0067","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","article-title":"Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"36","author":"Winston","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0068","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2021.05.001_bib0069","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo- controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2021.05.001_bib0070","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V93.5.1781","article-title":"Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients","volume":"93","author":"Boeckh","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0071","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbmt.2010.07.026","article-title":"An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients","volume":"17","author":"Pollack","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0072","first-page":"783","article-title":"CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections","volume":"13","author":"Bacigalupo","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0073","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1702450","article-title":"Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study","volume":"26","author":"Bregante","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0074","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/infdis\/166.3.473","article-title":"Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients","volume":"166","author":"Reusser","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0075","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/bmt.2013.164","article-title":"Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT","volume":"49","author":"Bontant","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0076","article-title":"A survey of pediatric bone marrow transplant centers regarding local cytomegalovirus prophylaxis management practices and interest in a future randomized trial","volume":"5","author":"Fisher","year":"2018","journal-title":"ID Week Vol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0077","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM198801143180202","article-title":"Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation","volume":"318","author":"Meyers","year":"1988","journal-title":"N Engl J Med"},{"issue":"8900","key":"10.1016\/j.jtct.2021.05.001_bib0078","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2021.05.001_bib0079","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0080","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.05.001_bib0081","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2011-06-361618","article-title":"Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients","volume":"118","author":"Milano","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0082","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.bbmt.2018.05.008","article-title":"A modified intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplantation recipients","volume":"24","author":"Hill","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0083","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","article-title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","volume":"132","author":"Allen","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0084","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminhematol.2018.04.011","article-title":"Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease","volume":"55","author":"Guilcher","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0085","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/bmt.2015.303","article-title":"Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood","volume":"51","author":"Solano","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0086","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.bbmt.2011.08.014","article-title":"Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies","volume":"17","author":"Mu\u00f1oz-Cobo","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0087","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1073\/pnas.140123497","article-title":"Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy","volume":"97","author":"Emery","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtct.2021.05.001_bib0088","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.bmt.1705341","article-title":"Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Ayala","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0089","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1399-3062.2006.00183.x","article-title":"Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation","volume":"9","author":"Busca","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0090","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bmt.1705311","article-title":"Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients","volume":"37","author":"van der Heiden","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0091","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2005-09-3786","article-title":"Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation","volume":"107","author":"Einsele","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0092","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0093","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1703251","article-title":"Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections","volume":"28","author":"Chakrabarti","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0094","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood.V98.5.1626","article-title":"Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients","volume":"98","author":"Kiehl","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0096","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood.V86.7.2815.2815","article-title":"Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation","volume":"86","author":"Einsele","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0097","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0098","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s12879-017-2854-2","article-title":"Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients","volume":"17","author":"Robin","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.11.006","article-title":"Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status","volume":"22","author":"Servais","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jtct.2021.05.001_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2021.05.001_bib0101","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bmt.1702226","article-title":"Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection","volume":"25","author":"Einsele","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0102","first-page":"782","article-title":"Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation","volume":"111","author":"Peggs","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0103","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0104","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbmt.2004.11.016","article-title":"Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation","volume":"11","author":"Fries","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbmt.2017.09.018","article-title":"Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation","volume":"24","author":"Hammerstrom","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0106","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1703916","article-title":"Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir","volume":"31","author":"Verma","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0107","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1705249","article-title":"Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning","volume":"37","author":"Kline","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0108","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bmt.1701827","article-title":"Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance","volume":"24","author":"Bilgrami","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0109","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/infdis\/174.5.907","article-title":"Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation","volume":"174","author":"Boeckh","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0110","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1086\/516484","article-title":"Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation","volume":"175","author":"Hebart","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0111","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.bbmt.2012.06.008","article-title":"Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation","volume":"18","author":"Kim","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0112","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jinf.2015.11.005","article-title":"Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant","volume":"72","author":"Mengarelli","year":"2016","journal-title":"J Infect"},{"issue":"3-4","key":"10.1016\/j.jtct.2021.05.001_bib0113","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1399-3062.2005.000111.x","article-title":"Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program","volume":"7","author":"Rossini","year":"2005","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0114","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood.V94.12.4029","article-title":"Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation","volume":"94","author":"Holmberg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.05.001_bib0116","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41409-020-01166-w","article-title":"Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study","volume":"56","author":"Styczynski","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0117","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2147\/IDR.S296927","article-title":"Off-label use of letermovir as preemptive anti-cytomegalovirus therapy in a pediatric allogeneic peripheral blood stem cell transplant","volume":"14","author":"Chiereghin","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jtct.2021.05.001_bib0118","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jpids\/piz050","article-title":"Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient","volume":"9","author":"Kilgore","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jtct.2021.05.001_bib0119","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1093\/jac\/dkz218","article-title":"Letermovir in paediatric HSCT recipients","volume":"74","author":"Strenger","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jtct.2021.05.001_bib0120","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiz141","article-title":"Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects","volume":"220","author":"Adler","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0121","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.05.001_bib0122","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2021.05.001_bib0123","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/ajt.15764","article-title":"Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation","volume":"20","author":"Marty","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0124","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","article-title":"Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients","volume":"221","author":"Douglas","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0125","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cis818","article-title":"State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician","volume":"55","author":"Egli","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jtct.2021.05.001_bib0126","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0127","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and cmv infection after allogeneic hematopoietic cell transplantation: the REACT Study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0128","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients","volume":"219","author":"El Haddad","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jmv.21727","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital","volume":"82","author":"Fleming","year":"2010","journal-title":"J Med Virol"},{"issue":"10","key":"10.1016\/j.jtct.2021.05.001_bib0130","doi-asserted-by":"crossref","first-page":"e74744","DOI":"10.1371\/journal.pone.0074744","article-title":"Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications","volume":"8","author":"Tey","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2021.05.001_bib0131","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bmt.1705825","article-title":"Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT","volume":"40","author":"Avetisyan","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2021.05.001_bib0132","doi-asserted-by":"crossref","first-page":"ofw107","DOI":"10.1093\/ofid\/ofw107","article-title":"Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients","volume":"3","author":"Navarro","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0133","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100787","article-title":"A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients","volume":"33","author":"Ljungman","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"23","key":"10.1016\/j.jtct.2021.05.001_bib0134","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00747-19","article-title":"A replication-defective human cytomegalovirus vaccine elicits humoral immune responses analogous to those with natural infection","volume":"93","author":"Liu","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0135","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","volume":"37","author":"Plotkin","year":"2019","journal-title":"Vaccine"},{"issue":"362","key":"10.1016\/j.jtct.2021.05.001_bib0136","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2021.05.001_bib0137","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14760584.2018.1526085","article-title":"A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection","volume":"17","author":"Diamond","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jtct.2021.05.001_bib0138","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/M19-2511","article-title":"Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial","volume":"172","author":"Aldoss","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jtct.2021.05.001_bib0139","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3026(15)00246-X","article-title":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial","volume":"3","author":"Nakamura","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0140","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0141","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0142","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/infdis\/jix357","article-title":"Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus","volume":"216","author":"Pei","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0143","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0144","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcmd.2007.07.003","article-title":"Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells","volume":"40","author":"Mackinnon","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0145","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0146","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood"},{"issue":"9393","key":"10.1016\/j.jtct.2021.05.001_bib0147","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2021.05.001_bib0148","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0149","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/infdis\/jix360","article-title":"Adoptive immunotherapy of viral infections: should infectious disease embrace cellular immunotherapy?","volume":"216","author":"Boeckh","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0150","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0151","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/00007890-199811270-00012","article-title":"Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients","volume":"66","author":"Ljungman","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2021.05.001_bib0152","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1083-8791(00)70010-3","article-title":"CMV antigenemia following bone marrow transplantation: risk factors and outcomes","volume":"6","author":"Osarogiagbon","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0153","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-3062.2011.00706.x","article-title":"A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group","volume":"14","author":"George","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0154","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1399-3046.2008.01084.x","article-title":"Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors","volume":"13","author":"Yoon","year":"2009","journal-title":"Pediatr Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2021.05.001_bib0155","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V67.4.1162.1162","article-title":"Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease","volume":"67","author":"Miller","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0156","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/tid.12398","article-title":"Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation","volume":"17","author":"Cohen","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0157","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.bbmt.2018.05.001","article-title":"Deleterious effect of steroids on cytomegalovirus infection rate after allogeneic stem cell transplantation depends on pretransplant cytomegalovirus serostatus of donors and recipients","volume":"24","author":"Suarez-Lledo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0158","doi-asserted-by":"crossref","first-page":"e13049","DOI":"10.1111\/tid.13049","article-title":"Impact of cumulative steroid dose on infectious diseases after allogenic hematopoietic stem cell transplantation","volume":"21","author":"Watanabe","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0159","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse","volume":"23","author":"Aversa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0160","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1365-2141.1997.2773094.x","article-title":"Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications","volume":"98","author":"Bacigalupo","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0161","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0162","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.bmt.1704334","article-title":"Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens","volume":"33","author":"Chakrabarti","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0163","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bmt.1701095","article-title":"Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors","volume":"21","author":"Matsuda","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0164","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12185-010-0597-6","article-title":"Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion","volume":"91","author":"Schmidt-Hieber","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0165","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.bbmt.2016.08.003","article-title":"Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies","volume":"22","author":"Baker","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0166","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/bmt.2016.69","article-title":"The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide","volume":"51","author":"Crocchiolo","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.001_bib0167","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2016.149880","article-title":"Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide","volume":"101","author":"Goldsmith","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.05.001_bib0168","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0169","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/bmt.2016.216","article-title":"Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections","volume":"51","author":"Raj","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.001_bib0170","doi-asserted-by":"crossref","first-page":"e12629","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0171","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","article-title":"Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings","volume":"94","author":"Tischer","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2021.05.001_bib0172","doi-asserted-by":"crossref","first-page":"e13096","DOI":"10.1111\/tid.13096","article-title":"Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.001_bib0173","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2007.06.006","article-title":"Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources","volume":"13","author":"Walker","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0174","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/TP.0000000000002396","article-title":"Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients","volume":"103","author":"Meesing","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2021.05.001_bib0175","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V82.5.1672.bloodjournal8251672","article-title":"Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation","volume":"82","author":"Einsele","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.001_bib0176","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/JCM.01670-06","article-title":"Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer","volume":"45","author":"Han","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2021.05.001_bib0177","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.001_bib0178","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study","volume":"88","author":"Boeckh","year":"1996","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:01:21Z","timestamp":1763002881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721008927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":178,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2666636721008927"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Society for Transplantation and Cellular Therapy Series: #3\u2014Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}